Who Paid My Doc
clonoSEQ
Device B-Cell Acute Lymphoblastic Leukemia
General payments
$1,230,828
Research payments
$5,791,944
Through program year 2022, $1,230,828 in general payments and $5,791,944 in research payments were reported against clonoSEQ (B-Cell Acute Lymphoblastic Leukemia).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
8 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | General | $589,453 | 2,325 |
| 2022 | Research | $592,903 | 438 |
| 2021 | General | $249,258 | 608 |
| 2021 | Research | $898,639 | 26 |
| 2020 | General | $301,976 | 300 |
| 2020 | Research | $2,221,518 | 970 |
| 2019 | General | $90,141 | 121 |
| 2019 | Research | $2,078,884 | 23 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2022.
The top 5 of 50 specialties; each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.
The top 5 of 47 states; each share is of general payments naming this product in 2022 where a state was reported.
Records
3,354 general · 1,457 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.